⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XLO News
Xilio Therapeutics, Inc. Common Stock
Xilio Therapeutics Announces Pricing of Underwritten Offering
globenewswire.com
XLO
GILD
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
globenewswire.com
XLO
GILD
ABBV
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
globenewswire.com
XLO
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
globenewswire.com
XLO
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
globenewswire.com
XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
XLO
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
globenewswire.com
XLO
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
globenewswire.com
XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
XLO